1、Customized Cell Screening Panels – Accelerate Preclinical Decision-Making for Anticancer Drugs

Industry Pain Point: Traditional drug screening models fail to simulate the human tumor microenvironment, leading to a disconnect between preclinical data and clinical outcomes, prolonged R&D cycles, and increased failure risks.

Value Proposition: Through customized primary tumor cell panels combined with a high-throughput screening platform, we enable precise prediction of drug responses and shorten the candidate drug validation cycle by more than 50%.

2、Service Overview

As a core link in preclinical anticancer drug screening, the customized cell panel service focuses on solving the bottleneck problems of drug targeting verification and efficacy prediction.

Industry Pain Points:

• Severe genetic drift in commercial cell lines, failing to reflect tumor heterogeneity in patients;
• 2D culture models cannot simulate the in vivomicroenvironment, resulting in low accuracy of drug efficacy prediction.

Solutions:

Based on a patient-derived primary tumor cell bank (300+ Chinese human samples), we construct personalized/disease-specific cell panels, combined with CRISPR gene editing and 3D organoid culture technologies, to achieve:

• High clinical relevance of drug efficacy prediction (consistency with PDX models >85%);
• Full-process screening support from target validation to dose optimization.

3、Our Services

1. Customized Cell Panel Construction

Sample Sources: Patient surgical/biopsy tissues, PDX model living samples, Chinese human-derived primary tumor cell bank (covering 8 cancer types such as liver cancer, lung cancer, gastric cancer);

Panel Types:

• Personalized Panels: Polyclonal cell lines from a single patient (3-5 strains), for individual medication guidance;
• Disease Panels: Combinations of multiple subtypes of specific cancer types (e.g., HER2+/TNBC breast cancer), supporting research on drug indication expansion.

2. High-Throughput Drug Screening

Technology Platforms:

• In Vitro Drug Sensitivity Screening (QuiGueTM-Quick3D): 3D organoid culture + automated CTG/MTT detection, completing dose gradient tests of 100+ compounds within 14-21 days;
• Gene Editing Validation: CRISPR-Cas9 to construct drug-resistant strains/KO cell lines for verifying target necessity.

Detection Indicators:

IC50 value, apoptosis rate, migration inhibition rate, metabolic activity (OCR/ECAR), etc.

3. Data and Report

• Provide multi-dimensional drug efficacy heatmaps, dose-response curves and mechanism correlation analysis (e.g., target expression – drug efficacy correlation);
• Output FDA submission format reports (including raw data and statistical analysis).

4、Technology Platforms and Advantages

Technology Platforms

1. Primary Cell Culture Platform:

• Conditionally Reprogrammed (CR) technology enables infinite proliferation of primary cells with passage stability >P15;
• Success rate >80% (30-50% average in literature).

2. High-Throughput Screening Platform:

Multifunctional microplate reader and plate chemiluminescence analyzer system support daily detection of 1000 samples in 96-well plates.

Differentiated Advantages

• The only integrated triple platform of clinicalsamples-PDX-organoids: supporting cross-validation of in vitro and in vivo data;
• Chinese population-specific database: covering 100+ high-frequency mutant genes in the Chinese population (e.g., HBV-related liver cancer mutation profiles).

5、Service Process

1. Requirement Confirmation (1 working day): Sign a non-disclosure agreement and confirm the panel type, detection indicators and compound library;
2. Cell Preparation (1 week): Cell culture;
3. Drug Efficacy Screening (1-2 weeks):
4. Pre-experiment to determine the dose range → formal screening → data quality control (CV < 15%);
5. Report Delivery (3 working days):
6. Including RAW data, statistical analysis charts and mechanism interpretation suggestions.
7. Full-cycle support: Dedicated project manager + online data platform for real-time progress tracking.

6、Quality Control and Compliance

Compliance Standards:

• Experimental operations comply with GLP-aligned specifications (ISO 9001:2015 certified);
• The data traceability system meets the electronic record requirements of 21 CFR Part 11.

Quality Control Measures:

• Cells: STR identification (9 loci) + mycoplasma detection (PCR method);
• Data: Double-blind review by two researchers + cross-validation on third-party platforms (e.g., Calibr company reference materials).

7、Case Studies

Case 1: Combined Screening of Liver Cancer Targeted Drugs

• Client’s Requirement: Evaluate the combined effect of a multi-kinase inhibitor and PD-1 antibody;
• Solution: Construct a primary cell panel of 10 Chinese liver cancer patients (including PD-L1+ subgroups);
• Results:

• Screen out sensitive patient subgroups (AXIN1 mutant type, TGI 78%);
• The matching degree of response rate in Phase I clinical verification reaches 82%.

Case 2: Research on Breast Cancer Drug Resistance Mechanism

• Solution: Construct osimertinib-resistant H1975 lung cancer strains and screen compounds to reverse drug resistance;
• Result: The test substance overcomes the drug resistance of the drug-resistant strains, achieves a tumor suppressive effect, and the TGI is increased to 70%.

8、Cooperation Advantages

• Full-cycle support: Provide complete data packages for the CMC pharmacodynamics module from target discovery to IND application;
• Efficiency guarantee: Standard process takes 28 working days (industry average 45 days), and urgent projects take 15 working days;
• Cost optimization: Panel reuse mechanism (a single panel supports ≥ 5 screenings), reducing the cost of a single test by 40%.

9、FAQ

Q1: Is the detection of ADC drug endocytosis supported?

Yes. Integrate pHrodo labeling and high-content imaging to quantify the endocytosis efficiency and lysosomal escape rate.

Q2: Can the data be used for FDA/EMA applications?

We can provide a complete GLP-aligned data package and assist in writing the non-clinical pharmacodynamics chapter.

10、Lab Highlights

View More

11、Contact Us

Consult Now:

• 📞Tel: +86 020-29065209
• 📧Email: xuguoquan@jennio-bio.com
• 💻Online Requirement Submission

Limited-time Benefits:

• First order gets a free 3D drug sensitivity screening (worth ¥20,000);
• Download the White Paper on In Vitro Screening of Antitumor Drugs: Get it Now